Open in interactive viewer → charts, metric popovers & call review

QT Imaging Buys a Medicare Code — and Pays For It in the Middle East

A landmark CMS payment decision lands the same quarter guidance gets cut, cash keeps draining, and the stock sits 36% below its August peak
QTI · Earnings Call · 2026-11-10

A reimbursement win, and a repricing of the year

For a micro-cap medical device company with a $31 million market value, there are two kinds of news. There is the incremental kind — another scanner shipped, another distribution agreement — and there is the structural kind. QT Imaging delivered both on 2026-11-10, in the same twenty minutes, and the market has so far treated them as a wash. The structural news is reimbursement. On November 4, CMS reversed an earlier proposed non-payment decision and created a separate Medicare hospital outpatient payment for diagnostic QT scan examinations, effective January 1, 2027, assigning the company's dedicated CPT code to an ambulatory payment classification with payment status indicator S. As the CEO put it, “CMS reverted earlier proposed non payment decision and established separate Medicare hospital outpatient payment for diagnostic QT scan examination effective January 1, 2027” — Raluca Dinu, Chief Executive Officer · 2026-11-10. That is a genuine change in the economic physics of the product: a hospital buying a half-million-dollar acoustic CT box now has a billing code and a payer classification to point at. It is also a genuine change versus what management told investors three months ago. On the August call, asked directly whether there would be add-on codes, the answer was flat: “we do not expect any additional or add on codes to the Category III starting in January” — Raluca Dinu, Chief Executive Officer · 2026-08-12. The expectation then was data collection against a Category III code; the outcome is payment. It is the rare case of a company under-promising on a regulatory catalyst. The keyword trail confirms how abruptly this entered the story — reimbursement, Medicare payment and billing are all fresh top-momentum terms this quarter, absent a year ago. The offsetting news is arithmetic. Full-year revenue guidance went from roughly $39 million to roughly $34 million, “We are revising our revenue expectation to approximately $34 million compared with our previous guidance of approximately $39 million” — Jay W. Jennings, Chief Financial Officer · 2026-11-10, attributed to shipment delays to distribution partners in Saudi Arabia and the UAE from regional conflict and disrupted shipping routes. The company declined to put a date on it: “we cannot responsibly commit to a shipment date while conditions remain uncertain” — Raluca Dinu, Chief Executive Officer · 2026-11-10. This is not an idiosyncratic excuse — Middle East conflict was a top-ten global theme in the June quarter and shows up in this reporting cycle across logistics and imaging names alike. QT Imaging is simply small enough that one closed shipping lane is 13% of its year. The stock, tellingly, is not waiting to find out which item matters more. It has fallen 25.6% since mid-August and sits 36% below its 2026-08-24 peak of $3.31 — a drawdown that began well before this print and that the CMS win has not reversed.

What management stopped saying

The most informative part of this call is the silence. Two themes that carried real weight in the prior quarter have simply evaporated. First, Pakistan. In August, an analyst opened the Q&A on it, and the CEO described “a sales agent agreement in Pakistan with a woman led company that is called Re:Invent” — Raluca Dinu, Chief Executive Officer · 2026-08-12, with systems expected to move "in the next few months." In November: no mention. The keyword itself, once a momentum gainer, has dropped out of the company's thematic set entirely. Second, the Mayo Clinic MRI comparison study — the 100-patient effort to show QT finds what MRI finds and to down-classify BI-RADS 4 lesions toward BI-RADS 3. That was the clinical centerpiece of the August call. It is gone from the November narrative, replaced by a different, less ambitious-sounding evidence set: roughly 13,000 women imaged cumulatively, and a repeatability study showing under 1% variability in speed-of-sound measurements. That is a legitimate claim — operator independence is the real wedge against handheld ultrasound — but it is a workflow claim, not a diagnostic-substitution claim. When a company swaps a hard clinical endpoint for an easier technical one, that is worth noticing. What replaced them is more commercially mature language, and it does show up in the keyword data: clinical adoption is now the company's single highest-momentum theme, alongside purchase orders and a rebuilt direct sales organization — three senior sales leaders now reporting to a Chief Commercial Officer, two on the East Coast and one on the West, versus the two VPs discussed in August. Add the Premier GPO agreement secured through NXT Imaging, giving pre-negotiated access to nearly 4,400 hospitals, and the go-to-market scaffolding finally looks like a system rather than a hope. The clinical target has sharpened too: dense breast diagnostics, explicitly not screening. Management was careful — Medicare payment applies to medically necessary, physician-ordered diagnostic exams, and routine screening remains uncovered. Half of US women have dense breasts; that is a large diagnostic market and a small screening one, and the company is now honest about which it is selling into.

The cash question behind the 75%

The headline is real: revenue of $7.3 million, up 75%, on 15 scanners versus 9, with 43 sold in the first nine months and 25 expected in Q4, 17 of them domestic. Gross margin held at 41.3%. But the accounting below the headline is where the scepticism lives. Operating loss widened to $2.4 million from $1.7 million as the sales build hit the P&L, and the reported net loss of roughly $297,000 exists only because of a $2.4 million non-cash gain on the earn-out liability — a fair-value swing, not an operating result. Meanwhile receivables were running at essentially 100% of revenue, which is why cash fell from $11 million at June 30 to $8.4 million at September 30 while the top line set records. Nine-month operating cash burn was $10.7 million against a $21.3 million revenue base. On the Q&A, the runway question was asked directly. The answer was a deferral, not a plan: “Do we plan to go out to the market for money not for now. We do feel that we have to close Q4 and see how the year ends up” — Raluca Dinu, Chief Executive Officer · 2026-11-10. Notably, the August keyword set flagged senior secured term loan and maturity-date language; neither resurfaces now. Silence on the capital structure while burning $2–3 million a quarter on an $8 million balance is the thing to watch, not the scanner count.

Our U. S. Scanner shipment plan is unchanged. We remain engaged with our partners with the timing of Middle East shipments and any associated revenue recognition remain uncertain.

Jay W. Jennings, Chief Financial Officer · 2026-11-10
The Q4 implication is the tell. A cut to $34 million still requires roughly $12.7 million in the fourth quarter — a 74% sequential jump and 25 scanners in three months, after 43 in the prior nine. Management insists the US plan is untouched and that GCC pricing is higher with lower COGS, lifting blended margin. If that lands, the CMS decision plus Premier access becomes a 2027 story with a clean handoff. If the shipping lanes stay shut, this quarter's 75% growth is a peak, not a base — and a company whose most valuable asset is a Medicare code it cannot yet bill against at scale will be back at the market for cash before it gets to use it. That is the tension worth holding: an unusually clean structural win, delivered by a company whose balance sheet gives it perhaps four quarters to exploit it.